← Leaderboards
Steven E Coutre
Stanford University
$227,396
Attributed
$227,396
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $62.6K · FY2006–08$100K$75K$50K$25K$0
'06
'07
'08
Funding mix
By agency
NIH$227,396 · 10
By mechanism
M01$227,396 · 10
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Christopher Y Park$11,341,558
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesUnited States National Institutes Of HealthSourceResearch PersonnelFundingComputer Retrieval Of Information On Scientific Projects DatabaseGrantSafetyInstitutionDrug KineticsClinical ResearchComplementAntibodiesDrug Screening /EvaluationB LymphocyteMonoclonal AntibodiesNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer Radionuclide TherapyClinical Trial Phase IBinding (Molecular Function)Chronic Lymphocytic LeukemiaHuman Therapy EvaluationClinical TrialsIodine
Grant awards (12)
CLINICAL TRIAL: ECULIZUMAB IN PATIENTS WITH TRANSFUSION DEPENDANT, HEMOLYTIC (PN$2,617
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: CAT-8015 IN PATIENTS WITH RELAPSED OR REFRACTORY HAIRY CELL LEUK$683
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ADULT PATIENTS W/RELAPSED OR REFRACTORY B-LINEAGE ACUTE LYMPHOBL$569
M01 · FY2008 · RR · contact PI
ECULIZUMAB IN PATIENTS WITH TRANSFUSION DEPENDANT, HEMOLYTIC PNH$32,182
M01 · FY2007 · RR · contact PI
SHEPHERD: SAFETY IN HEMOLYTIC PNH PATIENTS TREATED WITH ECULIZUMAB$23,405
M01 · FY2007 · RR · contact PI
ADULT PATIENTS W/ RELAPSED OR REFRACTORY B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA$7,022
M01 · FY2007 · RR · contact PI
USING ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS$9,340
M01 · FY2006 · RR · contact PI
PATIENTS WITH TRANSFUSION DEPENDANT (PNH)$8,896
M01 · FY2006 · RR · contact PI
SHEPHERD: SAFETY IN HEMOLYTIC PNH PATIENTS TREATED WITH ECULIZUMAB$8,006
M01 · FY2006 · RR · contact PI
ANTIB1 ANTIBODY FOR B CELL CHRONIC LYMPHOCYTIC LEUKEMIA$134,676
M01 · FY2001 · RR
ANTIB1 ANTIBODY FOR B CELL CHRONIC LYMPHOCYTIC LEUKEMIA$0
M01 · FY2001 · RR
ANTIB1 ANTIBODY FOR B CELL CHRONIC LYMPHOCYTIC LEUKEMIA$0
M01 · FY2000 · RR